For those living with progressive multiple sclerosis, time is not a neutral force — it is the disease itself, advancing without pause. The Octopus trial, a UK-based adaptive study now extending into Australia through the PLATYPUS program, is attempting to meet that urgency with a new kind of scientific architecture: testing multiple treatments simultaneously, cutting what fails, and pursuing what shows promise. Its first results have done exactly that — discontinuing metformin and advancing alpha lipoic acid — offering a signal, if not yet proof, that the model and perhaps the molecule are wor
World-first adaptive MS trial shows alpha lipoic acid promise, expands to Australia
People with progressive MS face inevitable disease progression; effective treatments could slow disability and provide hope for this population with significant unmet medical needs.